Pharmalicensing.com: PR Newswire http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us Pharmalicensing.com: PR Newswire http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 Shire to Add New Orphan Drug to its HGT Portfolio - EU Launch Imminent BASINGSTOKE, England and CAMBRIDGE, Massachusetts, July 3 /PRNewswire/ -- http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1338 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1338 Thu, 03 Jul 2008 08:30:00 +0000 Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics SAN DIEGO, June 3 /PRNewswire/ -- Gen-Probe Incorporated (Nasdaq: GPRO), a pioneer and leader in nucleic acid diagnostics for human disease, announced today that it has launched a conditional tender... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1139 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1139 Tue, 03 Jun 2008 13:22:00 +0000 Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results REHOVOT, Israel and JERSEY CITY, New Jersey, May 14 /PRNewswire/ -- Rosetta Genomics (Nasdaq: ROSG), today announced it will release first quarter financial results on May 21, 2008, before the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/992 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/992 Wed, 14 May 2008 13:30:00 +0000 Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C PRINCETON, New Jersey and MILAN, Italy, April 25 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the results of a 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/870 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/870 Fri, 25 Apr 2008 16:30:00 +0000 Torchmark Corporation Reports First Quarter 2008 Results MCKINNEY, Texas, April 16 /PRNewswire/ -- Torchmark Corporation (NYSE: TMK) reported today that for the quarter ended March 31, 2008, net income was US$1.29 per share compared with US$1.37 per share... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/809 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/809 Wed, 16 Apr 2008 21:00:00 +0000